IL142989A0 - Nucleotide and protein sequences of nogo genes and methods based thereon - Google Patents

Nucleotide and protein sequences of nogo genes and methods based thereon

Info

Publication number
IL142989A0
IL142989A0 IL14298999A IL14298999A IL142989A0 IL 142989 A0 IL142989 A0 IL 142989A0 IL 14298999 A IL14298999 A IL 14298999A IL 14298999 A IL14298999 A IL 14298999A IL 142989 A0 IL142989 A0 IL 142989A0
Authority
IL
Israel
Prior art keywords
nucleotide
protein sequences
methods based
nogo
nogo genes
Prior art date
Application number
IL14298999A
Other languages
English (en)
Inventor
Martin E Schwab
Maio S Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22316666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL142989(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of IL142989A0 publication Critical patent/IL142989A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
IL14298999A 1998-11-06 1999-11-05 Nucleotide and protein sequences of nogo genes and methods based thereon IL142989A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10744698P 1998-11-06 1998-11-06
PCT/US1999/026160 WO2000031235A2 (en) 1998-11-06 1999-11-05 Nucleotide and protein sequences of nogo genes and methods based thereon

Publications (1)

Publication Number Publication Date
IL142989A0 true IL142989A0 (en) 2002-04-21

Family

ID=22316666

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14298999A IL142989A0 (en) 1998-11-06 1999-11-05 Nucleotide and protein sequences of nogo genes and methods based thereon
IL142989A IL142989A (en) 1998-11-06 2001-05-06 Nucleotide and protein sequences of nogo genes and methods based thereon
IL198027A IL198027A (en) 1998-11-06 2009-04-06 Antibody of the NOGO gene, medicinal preparations containing the antibody and use of the antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL142989A IL142989A (en) 1998-11-06 2001-05-06 Nucleotide and protein sequences of nogo genes and methods based thereon
IL198027A IL198027A (en) 1998-11-06 2009-04-06 Antibody of the NOGO gene, medicinal preparations containing the antibody and use of the antibody

Country Status (27)

Country Link
US (4) US7781188B1 (ja)
EP (3) EP2093294B1 (ja)
JP (2) JP2003531566A (ja)
KR (1) KR100728405B1 (ja)
CN (3) CN1721444A (ja)
AT (1) ATE435232T1 (ja)
AU (1) AU774367C (ja)
BR (1) BR9915137A (ja)
CA (1) CA2350395C (ja)
CY (1) CY1110679T1 (ja)
CZ (1) CZ304224B6 (ja)
DE (1) DE69941059D1 (ja)
DK (1) DK1124846T3 (ja)
ES (2) ES2529196T3 (ja)
HK (1) HK1038027A1 (ja)
HU (1) HUP0301829A3 (ja)
IL (3) IL142989A0 (ja)
MX (1) MXPA01004598A (ja)
NO (1) NO332460B1 (ja)
NZ (1) NZ511683A (ja)
PL (1) PL204293B1 (ja)
PT (1) PT1124846E (ja)
RU (3) RU2304585C2 (ja)
SK (1) SK287323B6 (ja)
TR (1) TR200700740T2 (ja)
WO (1) WO2000031235A2 (ja)
ZA (1) ZA200103714B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
DK1098972T3 (da) * 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
PL204293B1 (pl) 1998-11-06 2009-12-31 Univ Zuerich Oczyszczone białko i jego zastosowanie, izolowany kwas nukleinowy, wektor do klonowania, rekombinowana komórka, sposób wytwarzania rekombinowanego białka, sposób identyfikacji rybozymu lub antysensownego kwasu nukleinowego, przeciwciało monoklonalne, zastosowanie przeciwciała, sposób wytwarzania przeciwciał poliklonalnych, izolowana próbka surowicy odpornościowej, zastosowanie surowicy odpornościowej i sposób wytwarzania przeciwciał monoklonalnych.
AU4216200A (en) * 1999-04-08 2000-10-23 Chiron Corporation Novel protein associated with cell stress response
US7186530B1 (en) 2000-04-07 2007-03-06 Chiron Corporation Protein associated with cell stress response
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
AU784349C (en) * 2000-01-12 2006-09-28 Yale University Nogo receptor-mediated blockade of axonal growth
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
GB0101312D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
EP1556409A1 (en) * 2002-10-31 2005-07-27 Pieris ProteoLab AG Soluble truncated polypeptides of the nogo-a protein
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
RU2362780C2 (ru) * 2003-12-22 2009-07-27 Глаксо Груп Лимитед Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
JP4960865B2 (ja) 2004-06-24 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄に関連する状態の処置
KR100659820B1 (ko) 2004-11-17 2006-12-19 삼성에스디아이 주식회사 리튬 이온 이차 전지
SG157418A1 (en) * 2004-12-01 2009-12-29 Univ Singapore Nogo a protein fragments as neuronal network- interacting peptides
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
WO2007014382A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant nogo-66 domain proteins
EP1952147A2 (en) 2005-11-16 2008-08-06 Novartis AG Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP2009541211A (ja) * 2006-05-24 2009-11-26 ミエリン リペア ファウンデーション， インコーポレイテッド 血液脳関門の透過性
CN101015683B (zh) * 2007-01-18 2010-07-21 复旦大学 人rtn4b蛋白在制备创伤愈合药物中的应用
NZ584911A (en) * 2007-11-02 2011-08-26 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
AU2008328370A1 (en) * 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
AU2010256880B2 (en) * 2009-06-02 2015-01-22 Opko Health, Inc. Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
RU2478646C1 (ru) * 2011-11-28 2013-04-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) Способ получения высокоаффинных поликлональных антител
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
JP6293892B2 (ja) * 2013-08-08 2018-03-14 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低侵襲処置用インジェクションデバイスおよびその使用
KR101685109B1 (ko) * 2014-12-22 2016-12-09 경북대학교 산학협력단 근육 분화, 재생, 또는 질환 상태와 관련된 노고-에이의 용도
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3250220B1 (en) * 2015-01-27 2020-03-11 Universität Zürich Agonists of the nogo-a s1pr pathway for the treatment of glioblastoma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
CA1173823A (en) 1980-08-26 1984-09-04 Leonard M. Hjelmeland Nondenaturing zwitterionic detergent for membrane biochemistry
CA1341401C (en) 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
EP0155433A1 (en) 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
SG50681A1 (en) 1988-06-13 1998-07-20 American Biogenetic Sciences Method for the production of monoclonal antibodies utilizing a germfree animal
KR100196540B1 (ko) 1988-11-04 1999-06-15 마틴 이. 샤브 축색성장 조절인자
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
WO1993000427A2 (en) 1991-06-24 1993-01-07 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5858708A (en) * 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO1998017687A2 (en) * 1996-10-25 1998-04-30 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP1042470A2 (en) * 1997-12-30 2000-10-11 Chiron Corporation Bone marrow secreted proteins and polynucleotides
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
DK1098972T3 (da) * 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
EP1107978A1 (en) * 1998-08-24 2001-06-20 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
PL204293B1 (pl) 1998-11-06 2009-12-31 Univ Zuerich Oczyszczone białko i jego zastosowanie, izolowany kwas nukleinowy, wektor do klonowania, rekombinowana komórka, sposób wytwarzania rekombinowanego białka, sposób identyfikacji rybozymu lub antysensownego kwasu nukleinowego, przeciwciało monoklonalne, zastosowanie przeciwciała, sposób wytwarzania przeciwciał poliklonalnych, izolowana próbka surowicy odpornościowej, zastosowanie surowicy odpornościowej i sposób wytwarzania przeciwciał monoklonalnych.
EP1147192A1 (en) * 1999-11-15 2001-10-24 Smithkline Beecham Plc Human nogo-c polynucleotide and polypeptide and their uses
US20030134301A1 (en) * 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain

Also Published As

Publication number Publication date
NZ511683A (en) 2004-06-25
CN101684155A (zh) 2010-03-31
ES2529196T3 (es) 2015-02-17
IL198027A (en) 2011-10-31
PL362990A1 (en) 2004-11-15
CZ304224B6 (cs) 2014-01-15
RU2304585C2 (ru) 2007-08-20
MXPA01004598A (es) 2002-04-24
US7425334B2 (en) 2008-09-16
ES2329635T3 (es) 2009-11-27
HUP0301829A2 (hu) 2003-08-28
CY1110679T1 (el) 2015-06-10
ZA200103714B (en) 2004-06-25
DE69941059D1 (de) 2009-08-13
EP2333064A1 (en) 2011-06-15
RU2432364C2 (ru) 2011-10-27
CA2350395A1 (en) 2000-06-02
NO332460B1 (no) 2012-09-24
TR200700740T2 (tr) 2007-04-24
NO20012223D0 (no) 2001-05-04
HUP0301829A3 (en) 2009-03-30
JP2012213406A (ja) 2012-11-08
EP2093294A1 (en) 2009-08-26
AU774367C (en) 2005-04-21
US20110086034A1 (en) 2011-04-14
KR100728405B1 (ko) 2007-06-13
EP1124846A2 (en) 2001-08-22
US20090162367A1 (en) 2009-06-25
RU2004103555A (ru) 2005-07-20
RU2358982C2 (ru) 2009-06-20
CN1721444A (zh) 2006-01-18
RU2001115705A (ru) 2004-03-10
RU2009103533A (ru) 2010-11-10
US20050260616A1 (en) 2005-11-24
NO20012223L (no) 2001-07-02
IL142989A (en) 2010-12-30
HK1038027A1 (en) 2002-03-01
PL204293B1 (pl) 2009-12-31
EP1124846A4 (en) 2002-06-12
PT1124846E (pt) 2009-10-08
CN1354755B (zh) 2010-06-02
EP2093294B1 (en) 2014-10-29
CZ20011608A3 (cs) 2001-10-17
DK1124846T3 (da) 2009-10-26
ATE435232T1 (de) 2009-07-15
SK6222001A3 (en) 2001-12-03
KR20020003353A (ko) 2002-01-12
WO2000031235A2 (en) 2000-06-02
EP1124846B1 (en) 2009-07-01
JP2003531566A (ja) 2003-10-28
AU774367B2 (en) 2004-06-24
CN1354755A (zh) 2002-06-19
CA2350395C (en) 2014-07-08
BR9915137A (pt) 2004-06-08
SK287323B6 (sk) 2010-07-07
AU1469200A (en) 2000-06-13
US7781188B1 (en) 2010-08-24
WO2000031235A3 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
IL142989A0 (en) Nucleotide and protein sequences of nogo genes and methods based thereon
WO2000003685A3 (en) Nitrilase homologs
HK1041009A1 (en) Characterization of the soc/crac calcium channel protein family soc/crac
WO2001032910A3 (en) 27 human secreted proteins
WO2001036432A3 (en) 18 human secreted proteins
WO2001034768A3 (en) 15 human secreted proteins
WO2001012776A3 (en) 18 human secreted proteins
WO2000077026A8 (en) 49 human secreted proteins
WO2001046394A3 (en) Mammalian protein phosphatases
WO2000063230A3 (en) 49 human secreted proteins
WO2001062891A3 (en) 207 human secreted proteins
WO2000058339A3 (en) 50 human secreted proteins
WO2001012775A8 (en) 25 human secreted proteins
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
WO2000043495A3 (en) 33 human secreted proteins
WO2000061624A8 (en) 48 human secreted proteins
WO2004074460A3 (en) Nucleotide and protein sequences of coc genes and methods based thereon
ATE278011T1 (de) Human dnase ii
WO2003052377A9 (en) 41 human secreted proteins
WO2000061596A8 (en) 50 human secreted proteins
WO2002099066A3 (en) 20 human secreted proteins
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression
WO2002057420A3 (en) 50 human secreted proteins
WO2001034767A3 (en) 22 human secreted proteins
WO2001034769A3 (en) 24 human secreted proteins